EUnetHTA release 2019 Winter edition of Magazine

The 2019 Winter edition of the EUnetHTA Magazine has been launched with several updates from the EU-wide HTA project. In this edition, EUnetHTA profiles Austria and the UK, discussed innovation and HTA with Giovanni Tafuri, and lists both completed joint HTA reports and priority topics for future reports.

Current ongoing EUnetHTA collaborative assessments include:

  • “Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy, a biologic, or have medical contraindications to such therapies”
  • “Poltatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DBCL)”
  • “Enasidenib for the treatment of adult patients with relapsed or refactory acute myeloid leukaemia (AML) with an isocitrate dehyogenase 2 (IDH2) mutation”
  • “SotagliflozinforType1diabetesmellitus”
  • “Prophylactic or therapeutic use of endoanchoring systems in Endovascular Aortic Aneurysm Repair (EV A R) “
  • “Screening for osteoporosis in general population”
  • “Regional hyperthermia for high-risk soft tissue sarcoma treatment”
  • “LBO laser for PVP in the treatment of Benign Prostatic Hyperplasia (BPH)”
  • “Irreversible electroporation in liver and pancreatic cancer”
  • “Robotic surgery in cardiovascular and visceral indications”
  • “The use of 3D printing for implants and splints in connection with surgery”
  • “Stool DNA testing (e.g. ColoAlert, ColoGuard) for early detection of colorectal cancer”

To find out more, read the full Magazine here.

Tagged with

Published 11. March 2019 in News, News EU